Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

The effects of guanfacine on context processing abnormalities in schizotypal personality disorder.

McClure MM, Barch DM, Romero MJ, Minzenberg MJ, Triebwasser J, Harvey PD, Siever LJ.

Biol Psychiatry. 2007 May 15;61(10):1157-60. Epub 2006 Sep 1.

PMID:
16950221
2.

Context-processing deficits in schizotypal personality disorder.

Barch DM, Mitropoulou V, Harvey PD, New AS, Silverman JM, Siever LJ.

J Abnorm Psychol. 2004 Nov;113(4):556-68.

PMID:
15535788
3.

Guanfacine treatment of cognitive impairment in schizophrenia.

Friedman JI, Adler DN, Temporini HD, Kemether E, Harvey PD, White L, Parrella M, Davis KL.

Neuropsychopharmacology. 2001 Sep;25(3):402-9.

4.

Neuropsychological performance in schizotypal personality disorder: evidence regarding diagnostic specificity.

Mitropoulou V, Harvey PD, Maldari LA, Moriarty PJ, New AS, Silverman JM, Siever LJ.

Biol Psychiatry. 2002 Dec 15;52(12):1175-82.

PMID:
12488063
5.

Context processing in schizotypal personality disorder: evidence of specificity of impairment to the schizophrenia spectrum.

McClure MM, Barch DM, Flory JD, Harvey PD, Siever LJ.

J Abnorm Psychol. 2008 May;117(2):342-54. doi: 10.1037/0021-843X.117.2.342.

6.

Neuropsychiatric effects of guanfacine in children with mild tourette syndrome: a pilot study.

Cummings DD, Singer HS, Krieger M, Miller TL, Mahone EM.

Clin Neuropharmacol. 2002 Nov-Dec;25(6):325-32.

PMID:
12469007
7.

Dual-task information processing in schizotypal personality disorder: evidence of impaired processing capacity.

Harvey PD, Reichenberg A, Romero M, Granholm E, Siever LJ.

Neuropsychology. 2006 Jul;20(4):453-60.

PMID:
16846263
8.

Visual-spatial learning and memory in schizotypal personality disorder: continued evidence for the importance of working memory in the schizophrenia spectrum.

McClure MM, Romero MJ, Bowie CR, Reichenberg A, Harvey PD, Siever LJ.

Arch Clin Neuropsychol. 2007 Jan;22(1):109-16. Epub 2006 Dec 11.

9.

Effects of the D1 dopamine receptor agonist dihydrexidine (DAR-0100A) on working memory in schizotypal personality disorder.

Rosell DR, Zaluda LC, McClure MM, Perez-Rodriguez MM, Strike KS, Barch DM, Harvey PD, Girgis RR, Hazlett EA, Mailman RB, Abi-Dargham A, Lieberman JA, Siever LJ.

Neuropsychopharmacology. 2015 Jan;40(2):446-53. doi: 10.1038/npp.2014.192. Epub 2014 Jul 30.

10.

Lack of effects of guanfacine on executive and memory functions in healthy male volunteers.

Müller U, Clark L, Lam ML, Moore RM, Murphy CL, Richmond NK, Sandhu RS, Wilkins IA, Menon DK, Sahakian BJ, Robbins TW.

Psychopharmacology (Berl). 2005 Oct;182(2):205-13. Epub 2005 Oct 19.

PMID:
16078088
11.

No improvement of posttraumatic stress disorder symptoms with guanfacine treatment.

Neylan TC, Lenoci M, Samuelson KW, Metzler TJ, Henn-Haase C, Hierholzer RW, Lindley SE, Otte C, Schoenfeld FB, Yesavage JA, Marmar CR.

Am J Psychiatry. 2006 Dec;163(12):2186-8.

PMID:
17151174
12.

Mutation of the alpha2A-adrenoceptor impairs working memory performance and annuls cognitive enhancement by guanfacine.

Franowicz JS, Kessler LE, Borja CM, Kobilka BK, Limbird LE, Arnsten AF.

J Neurosci. 2002 Oct 1;22(19):8771-7.

13.
14.

Reduced processing resource availability in schizotypal personality disorder: evidence from a dual-task CPT study.

Moriarty PJ, Harvey PD, Mitropoulou V, Granholm E, Silverman JM, Siever LJ.

J Clin Exp Neuropsychol. 2003 May;25(3):335-47.

PMID:
12916647
15.

Long-term, open-label extension study of guanfacine extended release in children and adolescents with ADHD.

Biederman J, Melmed RD, Patel A, McBurnett K, Donahue J, Lyne A.

CNS Spectr. 2008 Dec;13(12):1047-55.

PMID:
19179940
16.

Guanfacine potentiates the activation of prefrontal cortex evoked by warning signals.

Clerkin SM, Schulz KP, Halperin JM, Newcorn JH, Ivanov I, Tang CY, Fan J.

Biol Psychiatry. 2009 Aug 15;66(4):307-12. doi: 10.1016/j.biopsych.2009.04.013. Epub 2009 Jun 11.

PMID:
19520360
17.

Treatment of age-associated memory impairment with guanfacine.

McEntee WJ, Crook TH, Jenkyn LR, Petrie W, Larrabee GJ, Coffey DJ.

Psychopharmacol Bull. 1991;27(1):41-6.

PMID:
1862205
19.

Guanfacine for the treatment of cognitive disorders: a century of discoveries at Yale.

Arnsten AF, Jin LE.

Yale J Biol Med. 2012 Mar;85(1):45-58. Epub 2012 Mar 29. Review.

20.

Alpha-2 adrenergic challenge with guanfacine one month after mild traumatic brain injury: altered working memory and BOLD response.

McAllister TW, McDonald BC, Flashman LA, Ferrell RB, Tosteson TD, Yanofsky NN, Grove MR, Saykin AJ.

Int J Psychophysiol. 2011 Oct;82(1):107-14. doi: 10.1016/j.ijpsycho.2011.06.022. Epub 2011 Jul 19.

Items per page

Supplemental Content

Write to the Help Desk